Raymond James Financial Services Advisors, Inc. Zynerba Pharmaceuticals, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 25, 2023
SELL
$0.3 - $0.43 $90 - $129
-300 Reduced 2.11%
13,900 $4,000
Q1 2023

Apr 14, 2023
BUY
$0.4 - $0.67 $5,680 - $9,514
14,200 New
14,200 $6,000
Q4 2019

Feb 12, 2020
SELL
$5.61 - $8.57 $86,876 - $132,715
-15,486 Closed
0 $0
Q3 2019

Nov 07, 2019
BUY
$7.56 - $15.44 $16,359 - $33,412
2,164 Added 16.24%
15,486 $117,000
Q2 2019

Aug 06, 2019
BUY
$5.4 - $15.5 $71,938 - $206,491
13,322 New
13,322 $181,000

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email